Hemochromatosis, Erythrocytosis and the P.V617F Mutation
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Mattman A, Huntsman D, Lockitch G, Langlois S, Buskard N, Ralston D
. Transferrin receptor 2 (TfR2) and HFE mutational analysis in non-C282Y iron overload: identification of a novel TfR2 mutation. Blood. 2002; 100(3):1075-7.
DOI: 10.1182/blood-2002-01-0133.
View
2.
Barton J, Bertoli L, Acton R
. HFE C282Y and H63D in adults with malignancies in a community medical oncology practice. BMC Cancer. 2004; 4:6.
PMC: 356917.
DOI: 10.1186/1471-2407-4-6.
View
3.
Gehrke S, Pietrangelo A, Kascak M, Braner A, Eisold M, Kulaksiz H
. HJV gene mutations in European patients with juvenile hemochromatosis. Clin Genet. 2005; 67(5):425-8.
DOI: 10.1111/j.1399-0004.2005.00413.x.
View
4.
Raphael B, COOPERBERG A, NILOFF P
. The triad of hemochromatosis, hepatoma and erythrocytosis. Cancer. 1979; 43(2):690-4.
DOI: 10.1002/1097-0142(197902)43:2<690::aid-cncr2820430241>3.0.co;2-r.
View
5.
Andrikovics H, Meggyesi N, Szilvasi A, Tamaska J, Halm G, Lueff S
. HFE C282Y mutation as a genetic modifier influencing disease susceptibility for chronic myeloproliferative disease. Cancer Epidemiol Biomarkers Prev. 2009; 18(3):929-34.
DOI: 10.1158/1055-9965.EPI-08-0359.
View